Pava Partners exclusively advised the shareholders of Grünhorn Group (“Grünhorn”), one of Germany’s leading providers of medical cannabis, on a majority investment by HEAL Group (“HEAL”). The transaction was completed in July 2026.

With HEAL, Grünhorn gains a long-term strategic majority shareholder for the next phase of its development. Together, the parties intend to further strengthen Grünhorn’s position in the German market and support continued growth. Grünhorn will benefit from access to a broader procurement and partner network, as well as additional opportunities to further develop its product portfolio and existing platform.

Grünhorn Group combines mail-order pharmacy operations, pharmaceutical wholesaling, fulfillment and logistics, as well as telemedicine services within an integrated business model.

The German market has developed dynamically following recent regulatory reforms. Against this backdrop, scale, procurement capabilities, quality of care, compliance, and supply reliability are becoming increasingly important. Grünhorn has established infrastructure across these areas and holds a strong position in the German market.

HEAL is a privately held, international healthcare and health tech group with an operational presence in Canada, the United States, the United Kingdom, and Germany. Through Khiron, HEAL is already active in the German medical cannabis market.

HEAL invests in, develops, and acquires businesses across the healthcare value chain. Its focus is on integrated solutions connecting patients, healthcare professionals, and pharmacies. As a long-term strategic shareholder, HEAL brings international healthcare expertise, established knowledge of the German market, experience in building and scaling healthcare businesses, and an international network.

With HEAL as its new majority shareholder, Grünhorn gains a strong strategic foundation for its continued development in the German medical cannabis market. Grünhorn contributes its established market position, pharmaceutical infrastructure, and telemedicine capabilities, while HEAL adds operational experience in the German medical cannabis market, international healthcare expertise, and a broader network.

About Grünhorn Group

Grünhorn Group is an established provider in the German medical cannabis market. The company combines mail order pharmacy operations, pharmaceutical wholesaling, fulfillment and logistics, as well as telemedicine services, and works closely with physicians and pharmacies.

For more information, visit www.gruenhorn.de.

About HEAL Group

HEAL Group is a privately held, internationally active healthcare and health tech group with operations in Canada, the United States, the United Kingdom and Germany. HEAL invests in, develops and acquires companies providing solutions for more integrated and patient centred healthcare. Its portfolio includes Khiron Life Sciences, an international medical cannabis company. The group focuses on connecting patients, healthcare professionals and pharmacies and on building scalable business models across international healthcare markets.

For more information, visit www.healgroup.ca.